Selenium supplementation in the treatment of hemodialysis patients

Phase 3

• Conditions: Hemodialysis.; End stage renal disease; N18.6

• Registration Number: IRCT20170513033941N62
• Lead Sponsor: Islamic Azad University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 October 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Diabetic hemodialysis patients aged 45 to 75 years.

Exclusion Criteria

Patients taking antioxidant and/or anti-inflammatory supplements within 3 months prior to intervention
Patients with infectious diseases
Patients with malignant diseases

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expressed levels of PPAR-? gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.

Secondary Outcome Measures

Name	Time	Method
Expressed levels of TNF gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of TGF-ß gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of LDL-ox gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.